Fig. 5

Overall survival and relapse-free survival according to IDH1 and IDH2 mutational subgroups and allogeneic hematopoietic cell transplantation in CR1. Simon–Makuch plots for a and c overall survival and b and d relapse-free survival of AML patients with mutated IDH1 R132C, IDH1 R132H, IDH2 R140 and IDH2 R172 mutational subgroups treated with allogeneic hematopoietic cell transplantation (blue) or conventional consolidation (red), respectively; p-values were determined with Cox model with time-dependent modeling of alloHCT; time in months; ns = not significant